Advaxis (NASDAQ:ADXS) Sees Unusually-High Trading Volume

Advaxis, Inc. (NASDAQ:ADXS) shares saw unusually-high trading volume on Wednesday . Approximately 2,977,953 shares changed hands during trading, an increase of 630% from the previous session’s volume of 408,211 shares.The stock last traded at $0.43 and had previously closed at $0.42.

ADXS has been the topic of a number of analyst reports. HC Wainwright restated a “neutral” rating on shares of Advaxis in a research report on Wednesday, June 12th. Zacks Investment Research upgraded shares of Advaxis from a “sell” rating to a “hold” rating in a research report on Friday, August 9th. Finally, ValuEngine upgraded shares of Advaxis from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

The company has a 50-day moving average of $1.17. The firm has a market cap of $7.22 million, a PE ratio of -0.02 and a beta of 3.23.

Advaxis (NASDAQ:ADXS) last announced its earnings results on Monday, June 10th. The biotechnology company reported ($1.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.19) by ($0.13). Advaxis had a negative return on equity of 86.88% and a negative net margin of 126.12%. The business had revenue of $1.19 million for the quarter, compared to analyst estimates of $0.34 million. As a group, sell-side analysts forecast that Advaxis, Inc. will post -2.7 EPS for the current year.

Large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its position in shares of Advaxis by 53,633.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 51,047 shares of the biotechnology company’s stock worth $107,000 after purchasing an additional 50,952 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Advaxis by 71.1% during the 2nd quarter. Vanguard Group Inc. now owns 230,106 shares of the biotechnology company’s stock worth $481,000 after purchasing an additional 95,607 shares in the last quarter. Two Sigma Investments LP grew its position in shares of Advaxis by 2,468.2% during the 4th quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 355,415 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Advaxis by 143.7% during the 2nd quarter. Renaissance Technologies LLC now owns 501,000 shares of the biotechnology company’s stock worth $1,047,000 after acquiring an additional 295,444 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in shares of Advaxis by 5,970.3% during the 4th quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock worth $106,000 after acquiring an additional 553,031 shares in the last quarter. Hedge funds and other institutional investors own 7.78% of the company’s stock.

About Advaxis (NASDAQ:ADXS)

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

Further Reading: Bid-Ask Spread

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.